Further, proof-of-principle experiments demonstrated that ex vivo priming of CD8+ T-cells towards a single FcRn-targeted antigen expressed by tumor cells enables subsequent in vivo protection from the seeding of lung metastases. Here, CD8A is linked to neoplasm.